@ShinyBlackShoe @gabe_a_brooks might have &There are guidelines produced by Guys @MelanieDalby that address. Here is one paper https://t.co/afFahkBlsj others imminent but you and I know how long journals take! #SafetyFirst
RT @PinkieChambers: Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients | Sp…
RT @PinkieChambers: Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients | Sp…
RT @PinkieChambers: Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients | Sp…
RT @PinkieChambers: Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients | Sp…
Great paper, need to look at this topic further and undertake more in depth analysis of funding issues regarding testing population and look at colo-rectal population as well.
Very interesting paper! Hopefully, pre-treatment genotyping for DPYD, UGT1A1, TPMT, and other genes will be standard practice in the near future #pharmacogenomics #PrecisionMedicine
RT @PinkieChambers: Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients | Sp…
Something that I feel very strongly about - experience from a U.K. hospital. Cost neutral to test for dpd in background section of manuscript https://t.co/afFahkBlsj
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients | SpringerLink https://t.co/afFahkBlsj
#DPYD #genotyping should be routine practice before prescribing #fluoropyrimidines https://t.co/4S7xqN5mIW